Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study, PMID: 32511983
Tafasitamab: First Approval, PMID: 32946059
Tafasitamab-cxix, PMID: 33016999
Tafasitamab, PMID: 33355731
Antibodies to watch in 2020, PMID: 31847708
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 33202794
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients, PMID: 33230948
The use of tafasitamab in diffuse large B-cell lymphoma, PMID: 34285786
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, PMID: 29444231
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma, PMID: 33554668
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor, PMID: 34414843
Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide, PMID: 34376434
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia, PMID: 34343354
RE-MIND: Comparing tafasitamab + lenalidomide (L-MIND) with a real‑world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma, PMID: 34433649
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, PMID: 34196165
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL, PMID: 34354920
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, PMID: 34407608
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering, PMID: 33212776
Diffuse large B-cell lymphoma: new targets and novel therapies, PMID: 33820908
Lenalidomide in DLBCL: are we past the cell of origin?, PMID: 33989279
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas, PMID: 33770460
The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients, PMID: 23277329
Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report, PMID: 27178351
Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report., PMID:40524964
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study., PMID:40371897
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway., PMID:40175588
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States., PMID:40163049
Highlights from the 66th ASH Annual Meeting 2024., PMID:39970879
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma., PMID:39966020
Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis., PMID:39934427
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma., PMID:39849596
SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review., PMID:39613700
A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system., PMID:39425497
Sakemura RL, Manriquez Roman C, Horvei P, et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024;143(3):258-271., PMID:39361306
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:39356892
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy., PMID:39163620
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma., PMID:39152509
Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma., PMID:39011744
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab., PMID:38934068
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma., PMID:38853698
Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma., PMID:38661647
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts., PMID:38610966
Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze., PMID:38434528
Second-line treatment of diffuse large B-cell lymphoma: Evolution of options., PMID:38342663
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma., PMID:38299612
An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)., PMID:38288815
CD19 occupancy may drive CARs further., PMID:38236611
Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options., PMID:38202077
Tribulations of trials in aggressive lymphoma., PMID:38153771
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma., PMID:38068428
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy., PMID:37973893
Preclinical study of CD19 detection methods post tafasitamab treatment., PMID:37928552
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS., PMID:37879074
A new frontier for R-CHOP: is two better than one?, PMID:37856095
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study., PMID:37738563
Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma., PMID:37701883
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study., PMID:37646664
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach., PMID:37644352
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma., PMID:37600821
In brief: Tafasitamab (Monjuvi) for diffuse large B-cell., PMID:37516901
Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context., PMID:37492075
New treatment options in elderly patients with Diffuse Large B-cell Lymphoma., PMID:37465115
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma., PMID:37432417
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study., PMID:37369099
Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL)., PMID:37339097
Novel agents in relapsed/refractory diffuse large B-cell lymphoma., PMID:37294966
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)., PMID:37289353
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:37171597
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis., PMID:36915243
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL., PMID:36873252
For research use only. Not for human or drug use.
